학술논문
Robust and prototypical immune responses toward influenza vaccines in the high-risk group of Indigenous Australians.
Document Type
Academic Journal
Author
Hensen L; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.; Nguyen THO; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.; Rowntree LC; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.; Damelang T; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.; Koutsakos M; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.; Aban M; World Health Organization Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.; Hurt A; World Health Organization Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.; Harland KL; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.; Auladell M; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.; van de Sandt CE; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.; Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, 1066 CX Amsterdam, The Netherlands.; Everitt A; Menzies School of Health Research, Charles Darwin University, Darwin, NT 0810, Australia.; Blacker C; Menzies School of Health Research, Charles Darwin University, Darwin, NT 0810, Australia.; Oyong DA; Menzies School of Health Research, Charles Darwin University, Darwin, NT 0810, Australia.; Center for Global Infectious Disease Research (CGIDR), Seattle Children's Research Institute, Seattle, WA 98109.; Loughland JR; Menzies School of Health Research, Charles Darwin University, Darwin, NT 0810, Australia.; Immunology Group, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4029, Australia.; Webb JR; Menzies School of Health Research, Charles Darwin University, Darwin, NT 0810, Australia.; Wines BD; Immune Therapies Laboratory, Burnet Institute, Melbourne, VIC 3084, Australia.; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC 3010, Australia.; Department of Clinical Pathology, The University of Melbourne, Parkville, VIC 3010, Australia.; Hogarth PM; Immune Therapies Laboratory, Burnet Institute, Melbourne, VIC 3084, Australia.; Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC 3010, Australia.; Department of Clinical Pathology, The University of Melbourne, Parkville, VIC 3010, Australia.; Flanagan KL; Tasmanian Vaccine Trial Centre, Clifford Craig Foundation, Launceston General Hospital, Launceston, TAS 7250, Australia.; School of Health Sciences and School of Medicine, University of Tasmania, Launceston, TAS 7248, Australia.; Department of Immunology and Pathology, Monash University, Melbourne, VIC 3800, Australia.; School of Health and Biomedical Science, Royal Melbourne Institute of Technology, Melbourne, VIC 3000, Australia.; Plebanski M; School of Health and Biomedical Science, Royal Melbourne Institute of Technology, Melbourne, VIC 3000, Australia.; Wheatley A; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.; Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Melbourne, VIC 3010, Australia.; Chung AW; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.; Kent SJ; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.; Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Melbourne, VIC 3010, Australia.; Infectious Diseases Department, Melbourne Sexual Health Centre, Alfred Health, Central Clinical School, Monash University, Melbourne, VIC 3053, Australia.; Miller A; Indigenous Engagement, Central Queensland University, Townsville, QLD 4810, Australia.; Clemens EB; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.; Doherty PC; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia; pcd@unimelb.edu.au kkedz@unimelb.edu.au.; Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105.; Nelson J; Menzies School of Health Research, Charles Darwin University, Darwin, NT 0810, Australia.; Davies J; Menzies School of Health Research, Charles Darwin University, Darwin, NT 0810, Australia.; Department of Infectious Diseases, Royal Darwin Hospital, Darwin, NT 0810, Australia.; Tong SYC; Menzies School of Health Research, Charles Darwin University, Darwin, NT 0810, Australia.; Victorian Infectious Diseases Service, The Royal Melbourne Hospital and The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia.; Kedzierska K; Department of Microbiology and Immunology, University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3000, Australia; pcd@unimelb.edu.au kkedz@unimelb.edu.au.
Source
Publisher: National Academy of Sciences Country of Publication: United States NLM ID: 7505876 Publication Model: Print Cited Medium: Internet ISSN: 1091-6490 (Electronic) Linking ISSN: 00278424 NLM ISO Abbreviation: Proc Natl Acad Sci U S A Subsets: MEDLINE
Subject
Language
English
Abstract
Morbidity and mortality rates from seasonal and pandemic influenza occur disproportionately in high-risk groups, including Indigenous people globally. Although vaccination against influenza is recommended for those most at risk, studies on immune responses elicited by seasonal vaccines in Indigenous populations are largely missing, with no data available for Indigenous Australians and only one report published on antibody responses in Indigenous Canadians. We recruited 78 Indigenous and 84 non-Indigenous Australians vaccinated with the quadrivalent influenza vaccine into the Looking into InFluenza T cell immunity - Vaccination cohort study and collected blood to define baseline, early (day 7), and memory (day 28) immune responses. We performed in-depth analyses of T and B cell activation, formation of memory B cells, and antibody profiles and investigated host factors that could contribute to vaccine responses. We found activation profiles of circulating T follicular helper type-1 cells at the early stage correlated strongly with the total change in antibody titers induced by vaccination. Formation of influenza-specific hemagglutinin-binding memory B cells was significantly higher in seroconverters compared with nonseroconverters. In-depth antibody characterization revealed a reduction in immunoglobulin G3 before and after vaccination in the Indigenous Australian population, potentially linked to the increased frequency of the G3m21* allotype. Overall, our data provide evidence that Indigenous populations elicit robust, broad, and prototypical immune responses following immunization with seasonal inactivated influenza vaccines. Our work strongly supports the recommendation of influenza vaccination to protect Indigenous populations from severe seasonal influenza virus infections and their subsequent complications.
Competing Interests: The authors declare no competing interest.
(Copyright © 2021 the Author(s). Published by PNAS.)
Competing Interests: The authors declare no competing interest.
(Copyright © 2021 the Author(s). Published by PNAS.)